Please login to the form below

Not currently logged in
Email:
Password:

Viread

This page shows the latest Viread news and features for those working in and with pharma, biotech and healthcare.

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Gilead targets hep B in half a billion dollar deal with Precision BioSciences

Current HBV therapies, including Gilead’s own Hepsera, Viread and Vemlidy, focuses on inhibiting viral DNA replication but don't completely clear the virus.

Latest news

  • Gilead's Hepatitis B therapy Vemlidy granted EU approval Gilead's Hepatitis B therapy Vemlidy granted EU approval

    Gilead's Hepatitis B therapy Vemlidy granted EU approval. Treatment shows similar efficacy to the firm's Viread at one-tenth of dosage. ... Vemlidy (tenofovir alafenamide, TAF) is a once-daily oral treatment, and produces a similar antiviral efficacy to

  • Gilead's hepatitis B virus treatment set for European approval Gilead's hepatitis B virus treatment set for European approval

    The EMA advisors issued a positive opinion for Vemlidy (tenofovir alafenamide) after data from two phase III studies showed Vemlidy to be superior to its predecessor Viread (tenofovir disproxil) in both ... Due to TAF's greater plasma stability, Vemlidy

  • Prices of AZ and GSK drugs slashed in China Prices of AZ and GSK drugs slashed in China

    The reductions affect GlaxoSmithKline's hepatitis B and HIV therapy Viread (tenofovir), AstraZeneca's lung cancer drug Iressa (gefitinib) and Conmana (icotinib) - another lung cancer treatment made by Chinese firm Betta ... Pharmaceuticals. Viread's

  • Gilead boosts liver disease pipeline with $1.2bn acquisition Gilead boosts liver disease pipeline with $1.2bn acquisition

    Descovy (emtricitabine tenofovir alafenamide) can be paired with a range of third agents and is given at a dosage over 90% lower than Gilead's existing treatment Viread (tenofovir disoproxil fumarate).

  • Priority FDA review for new Gilead HCV combination therapy Priority FDA review for new Gilead HCV combination therapy

    The trials involved treatment-naïve and treatment-experienced adults with HBeAg-negative and HBeAg-positive chronic and showed that TAF was as effective as Gilead's older HBV therapy Viread (tenofovir

More from news
Approximately 4 fully matching, plus 32 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Atlantis Healthcare

Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...

Latest intelligence

EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
Peoples Award
Quality in Care Diabetes 2018: the best in innovative diabetes care
Awards highlight new evidence-based approaches to improving care...

Infographics